Arrowhead Pharmaceuticals (NASDAQ:ARWR) executives said the company is focusing its 2026 priorities on commercial execution for Redemplo, upcoming Phase 3 data in severe hypertriglyceridemia and readouts from several earlier-stage RNA interference programs.
Speaking at the 47th Annual Goldman Sachs Global Healthcare Conference, Vincent Anzalone, vice president of investor relations at Arrowhead, said the company has moved “from a strictly R&D organization into a now commercial organization,” while concentrating late-stage R&D spending and commercial build-out in cardiometabolic disease.
Commercial launch centers on patient identification
Daniel Apel, Arrowhead’s chief financial officer, said familial chylomicronemia syndrome, or FCS, remains an ultra-rare and underdiagnosed condition, but Arrowhead’s current estimate of the U.S. market is “well north of 6,000” patients. He said that assessment is based on the company’s early launch experience and the launch of Ionis Pharmaceuticals’ competing therapy, Tryngolza.
Apel said Arrowhead uses physician identification and consumer-based marketing to find patients, along with “proprietary” and “innovative” methods involving health systems and other channels. Anzalone added that patients can be identified on a standard lipid panel because FCS is characterized by extremely elevated triglycerides, often in the thousands of milligrams per deciliter compared with a normal reading of about 150 mg/dL.
Anzalone said FCS may be diagnosed through genetic testing or clinically in patients with the same syndrome but without a known genetic signature. He said disease education efforts by Arrowhead and competitors have helped identify patients earlier and refer them into specialty care.
“Between we and Ionis, there’s probably about 1,000 patients already that are on drug after just over a year of this class being in the market,” Anzalone said. He added that Arrowhead believes penetration remains below 10%, and possibly around 5%.
Payer discussions and switching from competitors
Apel said payer discussions have been “very good” and that many payers appear willing to align policies with Arrowhead’s clinical criteria rather than requiring additional diagnostic scoring hurdles. He said slightly more than 10% of current Redemplo prescriptions are switches from competitors, driven by a range of factors including efficacy, tolerability and convenience.
Apel said Arrowhead believes Redemplo is a more potent molecule and pointed to quarterly dosing versus monthly dosing as a convenience factor. He also noted that Redemplo’s label has no warnings, precautions or contraindications, while the competitor’s label includes hypersensitivity and thrombocytopenia.
Anzalone said the broader APOC3 inhibitor class is “transformational” for patients who previously relied on strict low-fat diets yet still faced severe triglyceride spikes and hospitalizations for pancreatitis.
Europe decision expected soon
Apel said Arrowhead has received a positive CHMP opinion in Europe for Redemplo covering both genetic and clinical FCS. He said the company is hopeful for European Medicines Agency approval “this month.” If approved, he said Arrowhead would be the only provider in Europe with clinical FCS included in its label.
Apel said the European commercial rollout will be slower than in the U.S. because pricing and reimbursement are handled country by country. Germany is expected to be first, with other markets following over the next 12 months.
SHASTA-3 and SHASTA-4 readout expected this summer
Anzalone said Arrowhead is looking for continued evidence of strong APOC3 reduction and triglyceride lowering in SHASTA-3 and SHASTA-4, along with a potential signal for reducing acute pancreatitis risk. He said the studies were not prospectively powered specifically to show an acute pancreatitis benefit, but prior data from Arrowhead and Ionis have suggested that lowering triglycerides in high-risk populations can reduce pancreatitis risk.
Asked what would constitute a good or great outcome, Anzalone said a “good scenario” would be a numerical reduction in acute pancreatitis risk versus placebo, while a “home run scenario” would be statistical significance. He said the exact risk reduction may be less important commercially than generating clinical data that physicians can understand and that could potentially be included in the clinical studies section of the label.
Anzalone said last patient, last visit for SHASTA-3 and SHASTA-4 was expected within weeks, followed by quality control, database lock and a top-line readout “sometime this summer.”
Arrowhead is also running SHASTA-5, which Anzalone said was designed partly to address European payer interest in clinical benefit data. He said the company would reassess the value of SHASTA-5 after seeing SHASTA-3 and SHASTA-4 data and the potential SHTG label for Tryngolza.
Pricing and pipeline updates
Apel said Arrowhead recently reduced Redemplo’s wholesale acquisition cost to $45,000, a move he said was well received by payers and reduced uncertainty in reimbursement discussions. He said Arrowhead currently expects to maintain one Redemplo price across future indications, including SHTG.
Anzalone also discussed Arrowhead’s obesity-related programs, ARO-INHBE and ARO-ALK7. He said data presented at EASL showed inhibin inhibition led to liver fat reductions, with the magnitude of the effect “a bit surprising.” In interim early clinical data, he said patients with type 2 diabetes receiving the therapy in combination with tirzepatide showed a doubling of weight loss and a tripling of fat loss, while patients with or without type 2 diabetes saw liver fat reductions in the 40% to 70% range after two doses.
Anzalone said Arrowhead is evaluating ARO-INHBE along two potential paths: as a treatment for MASH and as an add-on therapy to GLP-1 drugs for obesity.
About Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.
The company’s pipeline includes multiple candidates in various stages of development.
